RTI Surgical and Exactech Announce Strategic Partnership
UF startup and UF Innovate | Sid Martin Biotech alum RTI Surgical Holdings, Inc., a leading surgical implant company providing blue-chip OEM customers with a portfolio of tissue-based, synthetic and metal implants, has announced it has entered into a long-term strategic agreement with Gainesville-based and leading global medical device OEM Exactech, related to the development and supply of biologic bone substitutes.
Experimental Skin Cancer Vaccine Developed in Tampa Saves Woman’s Life
A vaccine developed by Morphogenesis, Inc., a UF startup and UF Innovate | Sid Martin Biotech alum, helped improve a patients condition.
AGTC Reports 12-Month Data From Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients With Mutations in the ACHM
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, reported 12-month data from its ongoing achromatopsia (ACHM) Phase 1/2 clinical trials, including data from all adult patients and low-dose pediatric patients.
As Director of UF Innovate’s Incubation Services, Mark Long ‘Got Stuff Done’
UF Innovate is saying goodbye to the man who wrote the book on business incubation. Mark Long, the author of several such... Read More
Revolutionizing the Science of Nerve Repair and Regeneration
Peripheral nerve damage is estimated to affect more than 20 million people in the United States, causing symptoms that range from mild discomfort to severe disability. Damage is often undiagnosed or untreated, and the current standard of care procedures can be associated with limitations that impact the quality of life. UF startup and UF Innovate | Sid Martin Biotech alum Axogen, Inc., a company focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair, aims to address these issues and provide more efficient treatment options to patients.
Karl LaPan, New UF Innovate Director, Plans Continued Growth, Success for Program
Following a record-breaking year of growth for Alachua’s biotechnology industry, the University of Florida’s programs for entrepreneurial incubation and innovation, UF Innovate, has hired a new director of incubation services who’s looking to continue the program’s upward trajectory.
Phase 3 ePHex Study: OxThera Reports Results
Sid Martin Biotech alum OxThera AB, a biopharma company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces results of its pivotal Phase 3 study.
Inspira Awarded $1.98M NIH Grant for Diabetes Therapy
Inspira Therapeutics was awarded a $1.98 million NIH grant to develop its polymeric biomaterial-based tolerogenic treatment for type 1 diabetes.
Morphogenesis Awarded SBIR Funding for Cervical Cancer Therapy
UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a clinical-stage biotechnology company, has obtained funding to develop a new therapeutic drug to treat cervical cancer.
entrinsic bioscience Secures $49 Million in Financing To Accelerate Development and Commercialization of Next Generation Functional Ingredients and Active Pharmaceutical Ingredients
UF startup and UF Innovate | Sid Martin Biotech resident entrinsic bioscience (EBS), a company pioneering a next-generation protein modulation technology, announced that it has secured $49 million in non-dilutive growth capital from Jefferies Group LLC's subsidiary, Jefferies Funding LLC (Jefferies).
